Header image

Theme A Session 6: HTLV-1 – is this important for Australia?

Tracks
.
Wednesday, September 26, 2018
11:00 AM - 12:30 PM
Ionic (Ground Floor)

Details

Understanding the nature of HTLV-1c virology, pathogenesis, clinical presentation, transmission, epidemiology and the concerns that this virus presents for Australian health.

Speaker

Lloyd Einsiedel
Head, Infection and Chronic Disease
Baker Institute

Clinical aspects of the pathogenesis and epidemiology of HTLV-1 in Central Australia

11:00 AM - 11:20 AM

Biography

Professor Damian Purcell
Professor of Virology and Theme Leader for Viral Infectious Diseases
Uni Melbourne, Doherty Institute

Virology of HTLV-1c in Australia and Melanesian Islands

11:20 AM - 11:40 AM

Audio Recording

Speaker Presentation

Biography

Mr James Cooney
Phd Student
The Walter And Eliza Hall Institute

Tenofovir Alafenamide Reduces Transmission of Human T-Leukeamia Virus 1 (HTLV-1) in a Humanised Mouse Model of Infection

11:40 AM - 12:00 PM

Abstract

Speaker Presentation

Biography

Mr Joel Liddle
Research Officer
Baker Institute

The Prevalence And Clinical Associations Of HTLV-1 Infection In A Remote Indigenous Community

12:00 PM - 12:15 PM

Abstract

Biography

Dr Caroline Bartolo
ID physician
Barwon Health

A Patient With Human T Leukaemia Virus Subtype 1 (Htlv-1) Associated Leukaemia/Lymphoma And Invasive Aspergillosis

12:15 PM - 12:30 PM

Abstract

Biography

Chair

Shane Schinke
Project Manager
Baker Heart & Diabetes Institute (Alice Springs)

Stuart Turville
Kirby Institute

loading